Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis

(2021) Stephen L Hauser et al.   NEUROLOGY

Five-years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension

(2020) Stephen L. Hauser et al.   NEUROLOGY

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials

(2020) Ludwig Kappos et al.   JAMA Neurology

BMI influences CD20 kinetics in multiple sclerosis patients treated with ocrelizumab

(2020) E. Signoriello et al.   Multiple Sclerosis and Related Disorders

B cells reappear less mature and more activated after their anti-CD20–mediated depletion in multiple sclerosis

(2020) Nitzan Nissimov et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO

(2020) Ekaterina Gibiansky et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial

(2020) Jerry S Wolinsky et al.   LANCET NEUROLOGY

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis

(2019) Benjamin Turner et al.   JOURNAL OF NEUROLOGY

Silent Progression in Disease Activity-Free Relapsing Multiple Sclerosis

(2019) et al.   ANNALS OF NEUROLOGY

Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis

(2019) Colm Elliott et al.   BRAIN

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis

(2019) Frederik Barkhof et al.   NEUROLOGY

Disease-Modifying Treatment in Progressive Multiple Sclerosis

(2018) John Robert Ciotti et al.   Current Treatment Options in Neurology

Multiple Sclerosis Pathology

(2018) Hans Lassmann   Cold Spring Harbor Perspectives in Medicine

Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease

(2018) Darius Häusler et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders

(2018) Gisa Ellrichmann et al.   JOURNAL OF NEUROLOGY

Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions

(2018) Colm Elliott et al.   Multiple Sclerosis Journal

Multiple sclerosis

(2018) Massimo Filippi et al.   Nature Reviews Disease Primers

Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients

(2018) Stefan Gingele et al.   Cells

Human immune compartment comparisons: Optimization of proliferative assays for blood and gut T lymphocytes

(2017) Jeffrey Dock et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study

(2017) Ludwig Kappos et al.   Multiple Sclerosis Journal

Targets of therapy in progressive MS

(2017) Hans Lassmann   Multiple Sclerosis Journal

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2017) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study

(2017) Ludwig Kappos et al.   Multiple Sclerosis Journal

Targets of therapy in progressive MS

(2017) Hans Lassmann   Multiple Sclerosis Journal

Progressive multiple sclerosis: from pathogenic mechanisms to treatment

(2016) Jorge Correale et al.   BRAIN

Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine

(2016) Robert Zivadinov et al.   Expert Review of Neurotherapeutics

Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine

(2016) Robert Zivadinov et al.   Expert Review of Neurotherapeutics

Pathological mechanisms in progressive multiple sclerosis

(2015) Don H Mahad et al.   LANCET NEUROLOGY

Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients

(2014) Arumugam Palanichamy et al.   JOURNAL OF IMMUNOLOGY

Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties

(2013) Christian Klein et al.   mAbs